Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NNMT | P40261 | 4/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | HCAR3 | P49019 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | GRM5 | P41594 | 1/20 | 0.42 |
| ▸ | HPGDS | O60760 | 2/20 | 0.41 |
| ▸ | F7 | P08709 | 1/20 | 0.41 |
| ▸ | F3 | P13726 | 1/20 | 0.41 |
| ▸ | SARM1 | Q6SZW1 | 1/20 | 0.41 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.41 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.41 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.41 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.41 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.41 |
| ▸ | SIRT4 | Q9Y6E7 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2674517 | 0.98 | NNMT (0.53) | NNMTSMN1; SMN2HCAR3KDM4EL3MBTL1 | |
| Hydrochloric Acid SCHEMBL5009849 | 0.98 | NNMT (0.53) | NNMTSMN1; SMN2HCAR3KDM4EL3MBTL1 | |
| SCHEMBL25569690 | 0.85 | NNMT (0.52) | NNMTSMN1; SMN2HCAR3KDM4EL3MBTL1 | |
| SCHEMBL12734188 | 0.84 | HCAR3 (0.49) | SMN1; SMN2HCAR3KDM4EL3MBTL1HPGDS | |
| SCHEMBL3464465 | 0.84 | NNMT (0.50) | NNMTSMN1; SMN2HCAR3KDM4EL3MBTL1 | |
| SCHEMBL185127 | 0.82 | HCAR3 (0.65) | HCAR3KDM4EALDH1A1ALOX15HSD17B10 | |
| SCHEMBL3132351 | 0.81 | NNMT (0.47) | NNMTSMN1; SMN2HCAR3KDM4EL3MBTL1 | |
| SCHEMBL1778519 | 0.81 | HCAR3 (0.46) | HCAR3KDM4EHPGDSALDH1A1ALOX15 | |
| SCHEMBL4299808 | 0.81 | CYP1A2 (0.40) | NNMTSMN1; SMN2HCAR3KDM4EHPGDS | |
| SCHEMBL18433935 | 0.80 | HCAR3 (0.55) | NNMTSMN1; SMN2HCAR3KDM4EL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210338558-A1 | USE OF COLLAGEN BINDING DOMAINS TO DELIVER PRODUCTS TO SKIN | FABIUS BIOTECHNOLOGY (US) | 2021-11-04 | — | — | US | claimed |
| WO-2020068665-A1 | USE OF COLLAGEN BINDING DOMAINS TO DELIVER PRODUCTS TO SKIN | FABIUS BIOTECHNOLOGY (US) | 2020-04-02 | — | — | WO | claimed |
| EP-2038264-B1 | TETRAZOLE-SUBSTITUTED ARYLAMIDES | HOFFMANN LA ROCHE (CH) | 2016-10-26 | — | — | EP | claimed |
| EP-1937652-B1 | PYRIMIDINE AMIDE COMPOUNDS AS PGDS INHIBITORS | AVENTIS PHARMA INC (US) | 2014-07-30 | — | — | EP | claimed |
| US-8524774-B1 | Topical two step polytherapy for treatment of psoriasis and other skin disorders | CYMBIOTICS, INC. (US) | 2013-09-03 | — | — | US | claimed |
| EP-1732896-B1 | SUBSTITUTED PYRIDONES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) | AVENTIS PHARMA INC (US) | 2012-12-12 | — | — | EP | claimed |
| US-8202863-B2 | 2-Phenyl-pyrimidine-5-carboxylic acid benzylamide; to treat allergic and/or inflammatory disorders, particularly disorders such as allergic rhinitis, asthma and/or chronic obstructive pulmonary disease | AVENTIS PHARMACEUTICALS INC. (US) | 2012-06-19 | — | — | US | claimed |
| US-20120107273-A1 | NEW PIPERAZINE COMPOUND AND USE THEREOF AS A HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-05-03 | — | — | US | claimed |
| EP-2009004-A1 | NOVEL PIPERAZINE COMPOUND, AND USE THEREOF AS HCV POLYMERASE INHIBITOR | Japan Tobacco, Inc. (JP) | 2008-12-31 | — | — | EP | claimed |
| US-20080227782-A1 | PYRIMIDINE AMIDE COMPOUNDS AS PGDS INHIBITORS | AVENTIS PHARMACEUTICALS INC (US) | 2008-09-18 | — | — | US | claimed |
| US-20080081818-A1 | therapeutic agent for hepatitis C; R)-4-(4-trifluoromethyl-benzenesulfonyl)-piperazine-1,3-dicarboxylic acid 3-(4-isopropyl-benzylamide) 1-pyridin-4-ylamide; enzyme inhibitors | JAPAN TOBACCO INC. (JP) | 2008-04-03 | — | — | US | claimed |
| EP-1884513-A1 | PYRAZOLE COMPOUND AND THERAPEUTIC AGENT FOR DIABETES COMPRISING THE SAME | Japan Tobacco, Inc. (JP) | 2008-02-06 | — | — | EP | claimed |
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | JAPAN TOBACCO INC. (JP) | 2007-02-08 | — | — | US | claimed |
| US-4141977-A | Treatment of psoriasis with 6-substituted nicotinamides, 2-substituted pyrazinamides and closely related compounds | YU RUEY J | 1979-02-27 | — | — | US | claimed |
| WO-2024217344-A1 | NAV1.8 INHIBITORS, PREPARATION METHOD THEREFOR AND USE THEREOF | 中国科学院上海药物研究所 | 2024-10-24 | — | — | WO | disclosed |
| CN-118324743-A | Nav1.8 inhibitor and preparation method and application thereof | 中国科学院上海药物研究所 | 2024-07-12 | — | — | CN | disclosed |
| US-11433025-B2 | Oil foamable carriers and formulations | VYNE THERAPEUTICS INC. (US) | 2022-09-06 | — | — | US | disclosed |
| US-4141977-A | Treatment of psoriasis with 6-substituted nicotinamides, 2-substituted pyrazinamides and closely related compounds | YU RUEY J | 1979-02-27 | — | — | US | disclosed |
| US-4067975-A | Treatment of psoriasis with 6-aminonicotinamide and thionicotinamide | YU RUEY J | 1978-01-10 | — | — | US | disclosed |
| US-4067975-A | Treatment of psoriasis with 6-aminonicotinamide and thionicotinamide | YU RUEY J | 1978-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080227782-A1 | PYRIMIDINE AMIDE COMPOUNDS AS PGDS INHIBITORS | HRH2, HRH1, LTC4S | NNMT 959/4885SMN1; SMN2 4671/4885HCAR3 472/4885 |
| US-20080081818-A1 | therapeutic agent for hepatitis C; R)-4-(4-trifluoromethyl-benzenesulfonyl)-piperazine-1,3-dicarboxylic acid 3-(4-isopropyl-benzylamide) 1-pyridin-4-ylamide; enzyme inhibitors | HAVCR2, AADAC, DNPEP | NNMT 708/4885SMN1; SMN2 4462/4885HCAR3 1471/4885 |
| US-11433025-B2 | Oil foamable carriers and formulations | LIPA, PTGER1, TTPA | NNMT 4760/4885SMN1; SMN2 260/4885HCAR3 4205/4885 |
| US-20120107273-A1 | NEW PIPERAZINE COMPOUND AND USE THEREOF AS A HCV POLYMERASE INHIBITOR | POLR1C, POLR2E, POLR2H | NNMT 1088/4885SMN1; SMN2 4299/4885HCAR3 4399/4885 |
| US-20210338558-A1 | USE OF COLLAGEN BINDING DOMAINS TO DELIVER PRODUCTS TO SKIN | COL14A1, COL2A1, COL1A1 | NNMT 4848/4885SMN1; SMN2 2228/4885HCAR3 811/4885 |
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | PYGL, GYS2, AGL | NNMT 2977/4885SMN1; SMN2 4705/4885HCAR3 1649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.